{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Assess disease-free interval and failure sites of a new treatment regimen.","groups":[{"description":"PREOPERATIVE:Patients receive cisplatin IV over 2 hours 3 times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.\n\nSURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.\n\nINTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.\n\nPOSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10.\n\nCisplatin: Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.\n\nPaclitaxel: Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10 Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation: Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nod","id":"OG000","title":"Treatment (Neoadjuvant, Adjuvant Chemotherapy and Radiation)"}],"populationDescription":"The data was not collected or analyzed due to discontinuation of study in early stages.","reportingStatus":"POSTED","timeFrame":"Up to one year","title":"Disease-free Interval and Failure Sites","type":"SECONDARY"}